文献速递血栓与止血

重型血友病A初治患者不同FVIII浓缩物抑制剂发生风险:PedNet登记研究更新

Inhibitor development according to FVIII concentrates in previously untreated patients with severe hemophilia A: update from the PedNet registry.
PubMed 文献 · J Thromb Haemost · 2026-05-12

抑制剂累计发生率为31.0%(95%CI 28.6%-33.4%),中位发生时间为12个暴露日。按浓缩物类别比较,血浆源性与重组、标准半衰期与延长半衰期之间抑制剂风险相似;个别产品中KogenateFS/HelixateNexGen和Fanhdi风险升高。

要点

  • 重型血友病A初治患者抑制剂累计发生率为31.0%,中位发生时间12个暴露日。
  • 血浆源性、标准半衰期重组和延长半衰期重组FVIII的抑制剂风险相似。
  • KogenateFS/HelixateNexGen和Fanhdi抑制剂风险较Advate升高。

核心结论

  • 重型血友病A初治患者中31.0%发生抑制剂,不同类别FVIII浓缩物间风险相似。
  • 个别产品分析显示KogenateFS/HelixateNexGen和Fanhdi抑制剂风险升高。

研究设计与样本

  • 基于PedNet登记的前瞻性队列研究。
  • 随访至抑制剂发生或50个暴露日,采用多变量Cox回归比较风险。

主要发现

  • 444例患者发生抑制剂,中位12个暴露日,累计发生率31.0%(95%CI 28.6%-33.4%)。
  • 与标准半衰期重组FVIII相比,血浆源性FVIII的RR为0.89(95%CI 0.69-1.14)。
  • 与标准半衰期重组FVIII相比,延长半衰期重组FVIII的RR为1.10(95%CI 0.75-1.61)。

临床怎么用

  • 临床选择FVIII浓缩物时需考虑个别产品的抑制剂风险差异。
  • 初治患者应密切监测抑制剂发生,尤其在前50个暴露日。

局限性

  • 缺乏正式初治患者研究,PedNet将继续评估个别FVIII浓缩物的抑制剂风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment of severe hemophilia A (SHA) with FVIII concentrates is complicated by the development of neutralizing inhibitors in about 30% during the first 50 exposure days (EDs). Despite extensive research, inhibitor risk of different FVIII concentrates remains to be elucidated. OBJECTIVES: This study aimed to analyze inhibitor development according to (classes of) individual FVIII concentrates in previously untreated patients (PUPs) with SHA. METHODS: PUPs with SHA born between 2000 and 2024 were followed until inhibitor development or 50 EDs. Inhibitor development according to classes of FVIII concentrates (ie, plasma-derived [pdFVIII] vs recombinant [rFVIII] and standard vs extended half-life [SHL-rFVIII vs EHL-rFVIII]) and individual concentrates used by ≥40 PUPs were compared using multivariable Cox regression (generating rate ratios [RR] with 95% CIs). RESULTS: One thousand five hundred three PUPs were included. Inhibitors developed in 444 PUPs after a median of 12 EDs (cumulative incidence, 31.0%; CI, 28.6%-33.4%). Compared to SHL-rFVIII, inhibitor risk was similar for pdFVIII (RR, 0.89; CI, 0.69-1.14) and EHL-rFVIII (RR, 1.10; CI, 0.75-1.61). Nine individual FVIII concentrates (5 SHL-rFVIII, 1 EHL-rFVIII, and 3 pdFVIII) were compare to Advate (n = 392): only KogenateFS/HelixateNexGen (n = 307; RR, 1.40; CI, 1.07-1.82, P, .013) and Fanhdi (n = 50; RR, 1.72; CI, 1.11-2.68; P, .024) showed increased inhibitor risk. CONCLUSION: Inhibitor development occurred in 31.0% of PUPs, with similar incidence across SHL-rFVIII, EHL-rFVIII, and pdFVIII. Analysis of individual concentrates showed increased inhibitor risk for Kogenate FS/Helixate NexGen (SHL-rFVIII) and for the first time for Fanhdi (pdFVIII). In the absence of formal PUP studies, PedNet will continue evaluating the inhibitor risk according to individual FVIII concentrates.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Fischer K, Olivieri M, Ranta S, et al. Inhibitor development according to FVIII concentrates in previously untreated patients with severe hemophilia A: update from the PedNet registry. J Thromb Haemost. 2026. PMID: 42119947. doi:10.1016/j.jtha.2026.04.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。